188 related articles for article (PubMed ID: 33967759)
21. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
[TBL] [Abstract][Full Text] [Related]
22. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
23. Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.
La Monica S; Madeddu D; Tiseo M; Vivo V; Galetti M; Cretella D; Bonelli M; Fumarola C; Cavazzoni A; Falco A; Gervasi A; Lagrasta CA; Naldi N; Barocelli E; Ardizzoni A; Quaini F; Petronini PG; Alfieri R
J Thorac Oncol; 2016 Jul; 11(7):1051-63. PubMed ID: 27006151
[TBL] [Abstract][Full Text] [Related]
24. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer.
Huang Q; Wang Q; Li D; Wei X; Jia Y; Zhang Z; Ai B; Cao X; Guo T; Liao Y
J Exp Clin Cancer Res; 2019 Mar; 38(1):129. PubMed ID: 30876460
[TBL] [Abstract][Full Text] [Related]
25. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
26. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of high-dose pulsatile gefitinib in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
Wan Y; Yuan Y; Pan Y; Zhang Y
Exp Ther Med; 2017 Jun; 13(6):3067-3074. PubMed ID: 28587381
[TBL] [Abstract][Full Text] [Related]
28. Picropodophyllotoxin Inhibits Cell Growth and Induces Apoptosis in Gefitinib-Resistant Non-Small Lung Cancer Cells by Dual-Targeting EGFR and MET.
Lee JY; Kang BY; Jung SJ; Kwak AW; Lee SO; Park JW; Joo SH; Yoon G; Lee MH; Shim JH
Biomol Ther (Seoul); 2023 Mar; 31(2):200-209. PubMed ID: 36281696
[TBL] [Abstract][Full Text] [Related]
29. ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells.
Qi M; Tian Y; Li W; Li D; Zhao T; Yang Y; Li Q; Chen S; Yang Y; Zhang Z; Tang L; Liu Z; Su B; Li F; Feng Y; Fei K; Zhang P; Zhang F; Zhang L
Oncotarget; 2018 Feb; 9(15):12020-12034. PubMed ID: 29552290
[TBL] [Abstract][Full Text] [Related]
30. Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells.
Misumi K; Sun J; Kinomura A; Miyata Y; Okada M; Tashiro S
Cancer Sci; 2016 Apr; 107(4):444-51. PubMed ID: 26825989
[TBL] [Abstract][Full Text] [Related]
31. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.
Chang TH; Tsai MF; Su KY; Wu SG; Huang CP; Yu SL; Yu YL; Lan CC; Yang CH; Lin SB; Wu CP; Shih JY; Yang PC
Am J Respir Crit Care Med; 2011 Apr; 183(8):1071-9. PubMed ID: 21037017
[TBL] [Abstract][Full Text] [Related]
32. Dual inhibition of EGFR and MET by Echinatin retards cell growth and induces apoptosis of lung cancer cells sensitive or resistant to gefitinib.
Oh HN; Lee MH; Kim E; Kwak AW; Seo JH; Yoon G; Cho SS; Choi JS; Lee SM; Seo KS; Chae JI; Shim JH
Phytother Res; 2020 Feb; 34(2):388-400. PubMed ID: 31698509
[TBL] [Abstract][Full Text] [Related]
33. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
Meng S; Wang G; Lu Y; Fan Z
Lung Cancer; 2018 Jul; 121():82-90. PubMed ID: 29858032
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
35. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
36. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
37. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
38. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
[TBL] [Abstract][Full Text] [Related]
39. Protease-activated receptor 2 induces migration and promotes Slug-mediated epithelial-mesenchymal transition in lung adenocarcinoma cells.
Tsai CC; Chou YT; Fu HW
Biochim Biophys Acta Mol Cell Res; 2019 Mar; 1866(3):486-503. PubMed ID: 30321617
[TBL] [Abstract][Full Text] [Related]
40. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]